Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sofinnova Ventures' New $440M Eighth Fund Exceeds Expectations And Makes Adjustments

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm wins higher commitments from limited partners, turning its health-care focus to late stage companies and forgoing high-tech investments.

You may also be interested in...



Vicept Management, VCs Team Up Again To Launch Aclaris With $21M

Newly launched dermatology start-up Aclaris brings the band back together, as Vicept’s core management and VCs begin a new endeavor in a sometimes-neglected sector.

Pain At The Pump: For Some VCs, Filling Up On Cash Is Easier Than For Others

Who has recently topped up, and who’s running on empty? START-UP’s annual gas-tank review of venture fundraising shows how consolidation has hit the sector hard in the past twelve months, as limited partners concentrate their money in specialized funds that have demonstrated an ability to deliver returns.

Euro Crisis Hits Investor Risk Appetite, But Opportunities Remain

There are good-value opportunities in Europe for VCs with money to invest, but those seeking new funds face an unprecedentedly tough challenge that’s compounded by euro uncertainty.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072899

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel